Lycia Therapeutics raises $365M in upsized Nasdaq IPO
Lycia Therapeutics (LYCA) raised $365.1M in its Nasdaq IPO, selling 20.29M shares at $18 each, including underwriters' options. The biotech firm focuses on therapeutics for autoimmune and allergic diseases, with lead candidates LCA-0061 and LCA-0321. The offering was managed by Jefferies, TD Cowen, Evercore ISI, and Guggenheim Securities, with LifeSci Capital as a passive manager.
How this was made
The 30-second read
Why it matters
The $365M raise provides runway for its pipeline (LCA‑0061, LCA‑0321) and may attract further institutional interest in the sector.
Market read
First‑day trading of LYCA introduces a new biotech ticker with a sizable capital raise, offering short‑term trading opportunities.
What to watch
Potential dilution for existing shareholders and the risk that clinical data for lead candidates may not meet expectations.
Background
Lycia Therapeutics is a clinical‑stage biotech focused on extracellular protein degradation for autoimmune and allergic diseases.
Ticker impact
Lycia Therapeutics completed a $365M Nasdaq IPO, issuing 20.3M shares at $18 each and beginning trading on Oct 23, 2026.
potential upside as investors absorb the fresh float and the capital raise signals growth funding
Large capital raise ($365M) and first day of trading create immediate demand; biotech sector interest supports a bullish bias.
Market effects
Adds a new listed biotech player, modestly expanding the healthcare/biotech sector exposure.
Boosts the Nasdaq biotech listing count, modestly supporting US biotech sentiment.
Limited to US markets; no immediate global macro effect.
Counterpoint
The IPO could be over‑priced at $18, leading to early sell‑offs as investors reassess valuation.
Key entities
- companyLycia Therapeutics, Inc.
Clinical‑stage biotech that completed its Nasdaq IPO.
- underwriterJefferies
Joint book‑running manager for the offering.
